Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
about
A Survey of Strategies to Modulate the Bone Morphogenetic Protein Signaling Pathway: Current and Future PerspectivesTargeting BMP signalling in cardiovascular disease and anaemiaUncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor SelectivitySurgical Excision of Heterotopic Ossification Leads to Re-Emergence of Mesenchymal Stem Cell Populations Responsible for Recurrence.The immunological contribution to heterotopic ossification disorders.Comparison of newly developed anti-bone morphogenetic protein 4 llama-derived antibodies with commercially available BMP4 inhibitors.Matters of context guide future research in TGFβ superfamily signaling.Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008-2015).Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition.Diffuse Intrinsic Pontine Glioma: Time for Cautious Optimism.Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.Signaling pathways and mesenchymal transition in pediatric high-grade glioma.Strategic Targeting of Multiple BMP Receptors Prevents Trauma-Induced Heterotopic Ossification.The Horizon of a Therapy for Rare Genetic Diseases: A "Druggable" Future for Fibrodysplasia Ossificans Progressiva.Novel Quinazolinone Inhibitors of ALK2 Flip between Alternate Binding Modes: Structure-Activity Relationship, Structural Characterization, Kinase Profiling, and Cellular Proof of Concept
P2860
Q26739015-5DDBA171-0C3F-47EF-9309-11C288C18A01Q26783734-166CD814-83A1-4592-B5FE-3FBC9FF95CB7Q28546110-42CBE9F1-B528-4458-A6A0-262353F246A9Q33722361-A42E9FBB-1DFA-4590-9062-59F1A1538339Q35563973-991C428A-A51D-4AA0-B15C-45766C65C9BFQ37138985-B1433DD7-817F-4110-A58D-82209DAD2396Q38612468-4D2D5AC9-E339-48C4-B6B0-00CEC407F3DCQ38835961-1B40D9C6-6F8D-41AC-BCB7-76D67A8DA346Q38928611-0315405B-31C8-4265-835E-1F4B84F0F4F8Q38963434-7BDD37E7-FCD3-4EB0-8112-73642F15892EQ47882574-5F97DA7A-750A-4466-BF12-A9067BF41ABCQ48258004-1F4C178E-B08B-4797-8569-E266CDE1D301Q50885568-A7E8EF54-655D-44E1-8609-7A2490B1C9F0Q52340220-1D038A47-4A70-40F9-9CB5-02B5F6E22E69Q58796966-C3566760-2173-4476-95B1-5E4A0D77A9C0
P2860
Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Structure-activity relationshi ...... s progressiva causing mutants.
@ast
Structure-activity relationshi ...... s progressiva causing mutants.
@en
Structure-activity relationshi ...... s progressiva causing mutants.
@nl
type
label
Structure-activity relationshi ...... s progressiva causing mutants.
@ast
Structure-activity relationshi ...... s progressiva causing mutants.
@en
Structure-activity relationshi ...... s progressiva causing mutants.
@nl
prefLabel
Structure-activity relationshi ...... s progressiva causing mutants.
@ast
Structure-activity relationshi ...... s progressiva causing mutants.
@en
Structure-activity relationshi ...... s progressiva causing mutants.
@nl
P2093
P2860
P356
P1476
Structure-activity relationshi ...... s progressiva causing mutants.
@en
P2093
Agustin H Mohedas
Alex N Bullock
Caroline E Sanvitale
Gregory D Cuny
Sungwoon Choi
Xuechao Xing
P2860
P304
P356
10.1021/JM501177W
P407
P577
2014-09-04T00:00:00Z